FDA Asked to Approve Talquetamab for Hard-to-treat Multiple Myeloma
Janssen has submitted an application with the U.S. Food and Drug Administration (FDA) asking that talquetamab be approved to treat relapsed or refractory…
Marisa Wexler, MS, senior science writer—
Articles by Marisa Wexler
Marisa Wexler, MS, senior science writer —
Articles by Marisa Wexler
Real-world Study Supports Blenrep for Hard-to-treat RRMM
The efficacy and safety of Blenrep (belantamab mafodotin) as a treatment for relapsed/refractory multiple myeloma (RRMM) in a real-world setting is similar to what…
OCEAN Trial Fails to Support Pepaxto for RRMM, FDA Panel Finds
An advisory panel to the U.S. Food and Drug Administration (FDA) has overwhelmingly decided that the Phase 3 OCEAN clinical trial did not provide sufficient…
Teclistamab Plus Darzalex Found to Ease Cancer Burden in Phase 1 Trial
A combination of the investigational therapy teclistamab and the approved medication Darzalex (daratumumab) reduced the cancer burden for most people with relapsed or refractory…
Nexpovio Triple Combo Approved as Myeloma Treatment in Europe
The European Commission has granted full approval to a triple combination therapy of Nexpovio (selinexor) — sold in the U.S. as Xpovio —  to treat…
Tecvayli Recommended for Conditional Approval in Europe
A branch of the European Medicines Agency (EMA) has recommended that Janssen’s investigational therapy Tecvayli (teclistamab) be granted conditional marketing authorization for adults with…
CYT-338 Shows Anticancer Activity in Preclinical Tests
CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer cells, has shown promising anti-cancer…
Europe Awaits Proposed New Framework for Sharing Health Data
The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the…
FDA Designates CT103A, CAR T-cell Therapy, an Orphan Drug
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CT103A, an experimental CAR T-cell therapy that IASO Biotherapeutics and…
Immune Therapy AO-176 Awarded FDA’s Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Arch Oncology‘s experimental immune-modulating therapy AO-176 as a potential treatment for…
